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Abstract Prader-Willi syndrome (PWS) is a genetic im-
printing disease that causes developmental and behavioral
disturbances resulting from loss of expression of genes
from the paternal chromosome 15q11-q13 region. In about
70% of subjects, this portion of the paternal chromosome is
deleted, while 25% have two copies of the maternal
chromosome 15, or uniparental maternal disomy (UPD;
the remaining subjects have imprinting center defects.
There are several documented physical and behavioral
differences between the two major PWS genetic subtypes
(deletion and UPD) indicating the genetic subtype plays a
role in clinical presentation. Serotonin is known to be
disturbed in PWS and affects both eating behavior and
compulsion, which are reported to be abnormal in PWS.
We investigated the tryptophan hydroxylase gene (TPH2),
the rate-limiting enzyme in the production of brain
serotonin, by analyzing three different TPH2 gene poly-
morphisms, transcript expression, and correlation with
PWS genetic subtype. DNA and RNA from lymphoblastoid
cell lines derived from 12 PWS and 12 comparison subjects
were used for the determination of genetic subtype, TPH2
polymorphisms and quantitative RT-PCR analysis. A
similar frequency of TPH2 polymorphisms was seen in
the PWS and comparison subjects with PWS deletion
subjects showing increased expression with one or more
TPH2 polymorphism. Both PWS deletion and PWS UPD
subjects had significantly lower TPH2 expression than
control subjects and PWS deletion subjects had significantly
lower TPH2 expression compared with PWS UPD subjects.
PWS subjects with 15q11-q13 deletions had lower TPH2
expression compared with PWS UPD or control subjects,
requiring replication and further studies to identify the
cause including identification of disturbed gene interactions
resulting from the deletion process.
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Introduction
Prader-Willi syndrome (PWS) is a genetic imprinting
disorder affecting about one in 20,000 live births (Butler
et al. 2006). PWS is caused by a disturbance in the
paternally-derived chromosome 15q11-q13 region (Bittel
and Butler 2005). In about 70% of subjects, this disturbance
results from a 15q11-q13 deletion, while 25% have
maternal uniparental disomy (UPD) due to both copies of
chromosome 15 inherited from the mother and the remain-
ing subjects have imprinting defects (Bittel and Butler
2005). Individuals with PWS present with infantile hypo-
tonia, hypogonadism, poor suck and feeding difficulties,
high pain threshold, compulsive tendencies and other
behavioral problems, mental deficiency for family back-
ground, short stature, small hands and feet, and perhaps the
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childhood and obesity due to hyperphagia and inability
to experience satiety (Holsen et al. 2009). PWS subjects
with the 15q11-q13 deletion and those with UPD have
distinct clinical differences (Butler et al. 2004; Cassidy et
al. 1997; Dimitropoulos et al. 2000; Holsen et al. 2009).
Overall, PWS subjects with 15q11-q13 deletions have more
“typical” PWS facial features, lower verbal IQ scores, a
higher incidence of obsessive-compulsive (OCD) behaviors,
skin-picking, and hypopigmentation (Butler et al. 2006;
Cassidy et al. 1997; Dimitropoulos et al. 2000). PWS
subjects with UPD tend to have higher incidences of
psychosis and social impairment, lower daily living scores,
and lower skill levels at tasks requiring spatial skills, like
jigsaw puzzles (Dykens and Shah 2003; Zarcone et al.
2007). The two groups have comparable degrees of
hyperphagia, and other PWS-associated physical traits such
as small hands and feet, hypoplastic genitalia and neonatal
hypotonia (Butler et al. 2006).
Perturbations in serotonin biology could account for
several of the behavioral problems seen in PWS subjects.
Serotonin is a neurotransmitter that plays a role in diverse
mental functions including mood, anxiety, alcohol and drug
dependency, food intake, sexual behavior, sleep regulation
and OCD (Veenstra-VanderWeele et al. 2000). Elevated
levels of serotonin have been observed in whole blood
samples from autistic subjects while significantly low levels
of the serotonin metabolite, 5-HIAA, were found in the
cerebrospinal fluid (CSF) of subjects with personality
disorders and those who committed or attempted suicide
due to unipolar depression (Veenstra-VanderWeele et al.
2000). Altered serotonin signaling in PWS subjects could
be caused by either abnormal expression of serotonin and/
or its receptors (e.g., 5HT2C) or altered serotonin metab-
olism. Interestingly, the 15q11-q13 region includes sequen-
ces for several non-coding RNAs that are normally
expressed only from the paternal chromosome including
47 nearly identical copies of the snoRNA HBII-52
(SNORD115) which influence expression of 5HT2C sero-
tonin receptors (Kishore and Stamm 2006). The snoRNA
HBII-52 promotes alternative splicing of 5HT2C, and
without the influence of HBII-52, a decrease in functional
5HT2C is present in the brain of PWS subjects. Further
evidence of disturbed serotonin biology in PWS includes
significantly higher levels of 5-HIAA in the CSF of PWS
subjects, indicating an elevated rate of metabolism and
serotonin turnover (Akefeldt et al. 1998). In addition, PWS
subjects generally respond positively to selective serotonin
reuptake inhibitors (SSRIs) with decreases in severity of
skin picking, OCD and aggressive tendencies (Dykens and
Shah 2003).
One mechanism for disturbance in serotonin signaling is
at the level of serotonin production from tryptophan
(Fig. 1). This neurotransmitter is produced by one of two
isoforms of tryptophan hydroxylase, TPH1 or TPH2. TPH1
is well-characterized and expressed primarily in the pineal
gland and in the gut, while TPH2 is expressed predomi-
nantly in the brain and has only recently been described
(Chen et al. 2008). Since its discovery, several gene
polymorphisms have been characterized. Relevant to our
study are three single nucleotide polymorphisms (SNPs) in
the 5’UTR of TPH2, two of which are in the promoter, -
703G/T and -473T/A, with the other SNP located in the
5’UTR of exon 1, +90A/G. Studies performed using in
vitro models have shown that these SNPs can affect TPH2
gene expression. For example, in primary serotonergic
neurons, the -473T/A polymorphism causes decreased
transcription from the TPH2 promoter, while a polymor-
phism at the +90A/G site causes increased expression
(Chen et al. 2008; Scheuch et al. 2007). The purpose of the
current study is to examine the effect of these SNPs on
TPH2 gene expression levels in PWS and control subjects
and to determine if there are relevant differences in TPH2
expression between the deletion and UPD genetic subtypes
of PWS.
Materials and methods
Subjects and genetic analysis After informed consent, 37
Caucasian PWS and 12 comparison subjects ranging in age
from 10–50 years were studied. Lymphoblastoid cell lines
were established via EBV infection from PWS and
cognitive/BMI/aged comparison subjects. PWS genetic
subtyping was performed as previously described to
determine deletion or UPD status (Bittel et al. 2006).
DNA was isolated from the lymphoblastoid cell lines and
PCR was performed to amplify an 1,154 bp fragment of the
TPH2 gene that includes all three relevant SNPs using the
following primers: forward 5’ ACTCTGCATAGAGGCAT
Fig. 1 Normal serotonin
biology in the human brain
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GTGCT 3’. Sequencing of the fragment was performed
using the ABI Genetic Analyzer 3100-Avant (Applied
Biosystems, Foster City, CA) and standard protocols.
Gene expression analysis Quantitative real-time PCR (RT-
PCR) was performed using the QuantiTect SYBR Green
One Step RT-PCR kit (Qiagen, Valencia, CA). Briefly,
RNA was isolated from actively growing lymphoblastoid
cell lines using Trizol reagent (Invitrogen, Carlsbad, CA).
RNA (500 ng) was combined with TPH2 or GAPDH (an
internal control housekeeping gene) specific primers along
with components necessary for both the reverse transcrip-
tion and the PCR amplification steps as described previ-
ously (Bittel et al. 2006). At least three replicates were run
for each sample. The reactions were carried out using the
ABI 7000 amplification system (Applied Biosystems,
Foster City, CA). For 45–50 cycles, the SYBR Green
fluorescence was measured during the extension step of
each cycle. Data was collected at the point at which the
intensity level crosses the cycle threshold (CT), defined as
the narrowest point between individual reactions in the
logarithmic phase of the reaction. TPH2 gene expression
was quantified using the comparative CT method. Briefly,
the ΔCT was calculated by subtracting the CT of the
housekeeping gene, GAPDH, from the TPH2 CT value for
each individual sample replicate. Then, the ΔΔCT value
was calculated by subtracting the ΔCT of a reference DNA
sample from each individual sample ΔCT value. Finally,




] as is standard for the comparative CT method.
Each sample was run in triplicate and an average was
calculated for each sample.
Results
Thirty-seven PWS subjects were originally analyzed
for the status of the TPH2 -703G/T SNP. Of these
subjects, six PWS subjects with UPD and six PWS
subjects with 15q11-q13 deletions exhibiting either
wild-type or differences in the -703G/T SNP were
selected for further analysis along with twelve compar-
ison subjects. Subjects were analyzed for three SNPs
(-703G/T, -473T/A, and +90A/G) in the TPH2 gene, as
well as TPH2 transcript expression (Fig. 2). Of the
twenty-four subjects selected for complete gene analysis,
15/24 or 62.5% were wild type for all 3 SNPs. There were
subjects who were heterozygous for one, two or three of
the SNPs, and one subject was homozygous for all three
SNPs. No significant difference was seen between PWS
and comparison subjects, or between PWS genetic
subtypes regarding the frequency of SNPs in the TPH2
gene.
A significant difference was observed between control,
PWS UPD and PWS 15q11-q13 deletion subjects in the
mRNA (transcript) expression of TPH2. The mean RQ
values (regardless of SNP status) for the control subjects,
PWS UPD and PWS deletion subjects were 1.152 +/-
0.100, 0.402 +/- 0.051 and 0.046 +/- 0.015, respectively
(Fig. 2). Compared to control subjects, PWS UPD subjects
have a 65% decrease in TPH2 expression, and PWS
deletion subjects have a 96% decrease in expression in
lymphoblastoid cell lines. PWS deletion subjects expressed
only 11.5% of the amount of TPH2 that PWS UPD subjects
expressed. Using the student’s T-test, the PWS deletion
subjects had statistically significantly decreased expression
compared to both control subjects (p<0.0001) and PWS
UPD subjects (p<0.0001). Overall, PWS UPD subjects also
had significantly less TPH2 expression than control
subjects (p<0.0001). PWS deletion subjects with TPH2
Fig. 2 Quantitative RT-PCR analysis of TPH2 mRNA level in PWS
15q11-q13 deletion subjects (n=6), PWS maternal disomy (UPD)
subjects (n=6), and control subjects (n=12). PWS deletion subjects all
showed lower TPH2 expression compared with PWS UPD or control




higher RQ values represent increased gene expression. TPH2
expression values were normalized to GAPDH (see Materials and
Methods section for details). Data are stratified by the genotype at
three separate SNP loci: -703G/T; -473T/A; +90A/G (wild type alleles
are in bold-face type)
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compared to subjects with the wild-type THP2 sequence.
PWS deletion subjects with no TPH2 polymorphisms (i.e.,
GG/TT/AA genotypes) had an average RQ value of 0.047,
while PWS deletion subjects with polymorphisms at each
TPH2 SNP locus had an average RQ value of 0.114
(p<0.0001).
Discussion
Since its initial description, several polymorphisms in the
TPH2 gene have been described (Chen et al. 2008;
Nielsen et al. 2008). Presence of these gene polymor-
phisms has been linked to conditions ranging from heroin
a d d i c t i o nt oO C Da n dd e p r e s s i o n( N i e l s e ne ta l .2008).
The three SNPs investigated in our study have been
previously shown to alter TPH2 gene expression. For
example, one study highlighted the role of the -473T/A
SNP indicating that it reduced TPH2 transcriptional
activity by 22% in primary serotonergic neurons (Scheuch
et al. 2007). A second study demonstrated that the
presence of the +90A/G polymorphism caused a signifi-
cant increase in expression using a luciferase reporter
assay in RN46A cells, a serotonergic rat raphe cell line
(Chen et al. 2008). In addition, electrophoretic mobility
shift assay (EMSA) analysis revealed that DNA-protein
interactions form with the wild-type +90A, indicating an
inhibitory element since changing this nucleotide to its G
polymorphism causes an increase in gene expression
(Chen et al. 2008). It is important to note that previous
studies have been performed in differing cell lines using
TPH2 plasmid constructs, while the goal of our study was
to measure endogenous TPH2 gene expression. Our
observation that the +90A/G SNP showed increased
TPH2 expression in PWS deletion subjects is in agreement
with the study published by Chen et al. (2008). We
observed that PWS deletion subjects with all wild-type
SNPs had the lowest overall expression of TPH2,
however, no difference was seen in the frequency of
TPH2 polymorphisms depending on whether subjects had
PWS or not. An important difference observed in our
study occurred between the two PWS genetic subtypes
(deletion or UPD). PWS subjects with 15q11-q13 dele-
tions had significantly lower TPH2 transcript expression
compared to PWS UPD subjects. Both PWS subtypes
exhibited significantly less TPH2 expression than control
subjects. Given these results, it is important to note that
the TPH2 gene, located on chromosome 12, is not within
the deleted chromosome 15q11-q13 region in PWS
subjects, suggesting that the decreased TPH2 expression
must be due to other factors associated with the deletion or
deletion process. There are paternally expressed snoRNAs
present in the 15q11-q13 region that influence 5HT2C
serotonin receptor post-transcriptional processing as
reported by Kishore and Stamm (2006). To the best of
our knowledge, a similar snoRNA-TPH2 interaction has
not been reported; however, we cannot rule out a possible
influence on TPH2 expression. Furthermore, a trans effect
involving a disturbed gene network could account for
these disturbances. Other non-coding RNAs such as
microRNAs not previously identified in the 15q11-q13
region could play a role or result from position effect of
other genes near the 15q11-q13 region impacted by the
deletion process.
This difference in TPH2 expression between PWS
deletion and UPD subjects, if replicated, has important
implications in differences in clinical symptoms found in
the two genetic subtypes which could impact therapeutic
interventions and research. The role of serotonin in the
different findings such as compulsions and skin picking in
PWS subjects, particularly those with the 15q11-q13
deletion, needs further investigation. These studies should
also include investigation of serotonin metabolism in PWS
given evidence of elevated 5-HIAA levels in CSF, another
finding supporting irregular serotonin biology in PWS
subjects. Our study introduces a key physiological differ-
ence in serotonin biology between PWS subjects with
15q11-q13 deletions and those with PWS UPD and offers
insight into medical treatment and therapeutic practices for
these subjects.
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